Emmaus Life Sciences, Inc. Announces Resignation of Masaharu Osato as Member of the Board of Director
September 01, 2022 at 01:31 am IST
Share
On September 28, 2022, Dr. Masaharu Osato resigned as a member of the Board of Directors of Emmaus Life Sciences, Inc. for personal reasons and expressed his best wishes to the company and his continued support as a longtime investor and stockholder. Dr. Osato's resignation leaves two vacancies on the five-person Board, and the Board is in the process of identifying potential candidates to fill the vacancies.
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Companyâs lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainosâs IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.